Literature DB >> 26082597

Bupropion-Induced Erythema Multiforme.

Alper Evrensel1, Mehmet Emin Ceylan1.   

Abstract

Entities:  

Year:  2015        PMID: 26082597      PMCID: PMC4466293          DOI: 10.5021/ad.2015.27.3.334

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


× No keyword cloud information.
Dear Editor: Drug reactions affecting the skin are more common than other parts of the body. Most drug-related skin reactions are easily treated benign lesions. However, in rare cases, severe lesions may also be observed. Skin reactions are particularly common in women, elderly people, people of African ancestry, multidrug users, and people with serious diseases. The frequency of skin reactions due to psychotropic drugs is reported to be 0.1%; almost one-third of them are due to antidepressants1. The frequency of skin reactions is 0.54% among 109,000 people taking antidepressants2. Bupropion is a new-generation antidepressant that mainly inhibits dopamine (by approximately 25%) and less substantially noradrenaline reuptake in neurons3. It is generally well tolerated. This prevalence of rash and pruritus in patients taking bupropion is 3.7%2. Here, we report a case of bupropion-induced erythema multiforme. A 31-year-old woman with depression was being treated with bupropion 150 mg/day. On the sixth day of treatment, she started to suffer from headache, fatigue, and sub-febrile fever. In addition, vesicular lesions surrounded by pink areas developed on the upper extremities (Fig. 1).
Fig. 1

Two, 2~3 cm, vesicular lesions on the right forearm.

Therefore, dermatological consultation was requested. As a result, she was diagnosed with erythema multiforme. The possible causes of this disease were investigated. No pathologies were identified from the results of a hemogram, routine biochemical tests, thyroid function tests, erythrocyte sedimentation rate, full urine examination, or electrocardiography. Neither a provocation test nor skin test was performed. She had no remarkable disease history or allergic reaction. Therefore, bupropion treatment was terminated. Upon treatment termination, the lesions regressed, leaving hyperpigmentation starting from the third day and were completely healed within two weeks (Fig. 2).
Fig. 2

Skin lesions after the termination of the bupropion treatment.

A few cases of erythema multiforme caused by bupropion have been reported4,5. If a skin reaction caused by an antidepressant occurs, the drug must be ceased immediately, followed by a washout period of one week or 3~4 half-lives of the drug before starting a new antidepressant from another group. As the skin lesions in such cases are generally type 1 hypersensitivity reactions, a new antidepressant from a different class must be administered. Clinicians should be aware of antidepressant-induced skin reactions and inform their patients about digestive, psychiatric, metabolic, autonomic, neurologic, and sexual side effects of antidepressants.
  5 in total

1.  Erythema multiforme associated with bupropion use.

Authors:  R Carrillo-Jimenez; M Zogby; T L Treadwell
Journal:  Arch Intern Med       Date:  2001-06-25

2.  Bupropion-induced erythema multiforme.

Authors:  T W Lineberry; G E Peters; J M Bostwick
Journal:  Mayo Clin Proc       Date:  2001-06       Impact factor: 7.616

Review 3.  Dermatologic side effects of psychotropic medications.

Authors:  Mario V Mitkov; Ryan M Trowbridge; Benjamin N Lockshin; Jason P Caplan
Journal:  Psychosomatics       Date:  2013-10-04       Impact factor: 2.386

Review 4.  Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.

Authors:  S H Preskorn
Journal:  J Clin Psychiatry       Date:  1995       Impact factor: 4.384

5.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

Authors:  Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004
  5 in total
  1 in total

1.  Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3.

Authors:  Alireza Karimollah; Anahid Hemmatpur; Taha Vahid
Journal:  Inflammopharmacology       Date:  2021-07-03       Impact factor: 4.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.